Dovitinib dilactic acid
Based on 12 publication(s) in Google Scholar
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis.
For research use only. We do not sell to patients.
- CAS No.: 852433-84-2
- Formula: C27H33FN6O7
- Molecular Weight:572.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10065
AxitinibTyrosine Kinase Inhibitor -
HY-10208
PazopanibVEGFR Inhibitor -
HY-10337
BrivanibVEGFR2 Inhibitor -
HY-10981
LenvatinibVEGFR/FGFR Inhibitor -
HY-119367
ODM-203FGFR/VEGFR Inhibitor -
HY-12009
Pazopanib Hydrochloridec-Kit Inhibitor -
HY-12432
GilteritinibFLT3/AXL Inhibitor -
HY-10407
SU 5402Tyrosine Kinase Inhibitor -
HY-13001
QuizartinibFLT3 Inhibitor -
HY-10065R
Axitinib (Standard)Tyrosine Kinase Inhibitor -
HY-10517
OrantinibTyrosine Kinase Inhibitor -
HY-10260
VandetanibVEGFR2/3 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Dovitinib dilactic acid
More- Nat Commun. 2025 Jul 24;16(1):6777. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]
- Acta Pharm Sin B. 2026 Feb 10.
- NPJ Precis Oncol. 2021 Jul 16;5(1):66. [Abstract]
- Front Cell Dev Biol. 2020 May 7:8:287. [Abstract]
- J Biol Chem. 2023 Apr;299(4):104595 [Abstract]
- BMJ Open Ophthalmol. 2026 Jan 12;11(1):e002307. [Abstract]
- Preprints. 2026 Jun 19.
- University of Düsseldorf. 2024.
- bioRxiv. 2024 June 09.
- Biochemistry for Health, NOVA University of Lisbon. 2019 Jul.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
WB
-
WB
All VEGFR Isoforms
More
Biological Activity
Description
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 852433-84-2
-
Molecular Weight 572.59
-
Formula C27H33FN6O7
-
SMILES
CC(O)C(O)=O.CC(O)C(O)=O.O=C1NC2=C(C(F)=CC=C2)C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3
-
Synonyms
CHIR-258 dilactic acid; TKI258 dilactic acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
PEAK1 maintains tight junctions in intestinal epithelial cells and resists colitis by inhibiting autophagy-mediated ZO-1 degradation. [Abstract]2025 Jul 24;16(1):6777. PMID: 40707483 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Theranostics
Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway. [Abstract]2018 Jul 30;8(15):4262-4278. PMID: 30128052
Dovitinib dilactic acid purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]
BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefinitib at 2.5 µM, Sunitinib at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.
-
-
NPJ Precis Oncol
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. [Abstract]2021 Jul 16;5(1):66. PMID: 34272467
Dovitinib dilactic acid purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2021 Jul 16;5(1):66. [Abstract]
3T3 cells expressing either the FGFR2 variant or KRAS G12V were incubated with a specified concentration of inhibitor for 5 days. Cell viability was measured using the PrestoBlue cell viability assay and plotted against an untreated control group.
-
Front Cell Dev Biol
2020 May 7:8:287. PMID: 32457900
Dovitinib dilactic acid purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2020 May 7:8:287. [Abstract]
Determination in L3.6 cells of FGF2-induced FGFR phosphorylation by Western blot in the presence of Dovitinib. FGFR1 and alpha-Tubulin are used as loading controls.
-
J Biol Chem
2023 Apr;299(4):104595 PMID: 36898579
Dovitinib dilactic acid purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2023 Apr;299(4):104595 [Abstract]
Gcn2 KO HEK293 cells were transfected with empty vector (−), WT, K619A, T899A, or M2 Gcn2. Cells were treated with vehicle, 50 nM Gcn2iB, 1 μM neratinib, 2 μM dovitinib, or 2 μM dabrafenib for 6 h and then Atf4-Luc activity was measured and presented normalized to vehicle-treated cells with empty vector.
-
BMJ Open Ophthalmol
Impact of anticancer drugs on human Tenon's fibroblast proliferation: implications for glaucoma surgery. [Abstract]2026 Jan 12;11(1):e002307. PMID: 41526033 -
-
-
-
Solvent & Solubility
In Vitro:
DMSO : ≥ 30 mg/mL (52.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
References
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7465 mL | 8.7323 mL | 17.4645 mL | 43.6613 mL |
| 5 mM | 0.3493 mL | 1.7465 mL | 3.4929 mL | 8.7323 mL | |
| 10 mM | 0.1746 mL | 0.8732 mL | 1.7465 mL | 4.3661 mL | |
| 15 mM | 0.1164 mL | 0.5822 mL | 1.1643 mL | 2.9108 mL | |
| 20 mM | 0.0873 mL | 0.4366 mL | 0.8732 mL | 2.1831 mL | |
| 25 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.7465 mL | |
| 30 mM | 0.0582 mL | 0.2911 mL | 0.5822 mL | 1.4554 mL | |
| 40 mM | 0.0437 mL | 0.2183 mL | 0.4366 mL | 1.0915 mL | |
| 50 mM | 0.0349 mL | 0.1746 mL | 0.3493 mL | 0.8732 mL |
Dovitinib dilactic acid Related Classifications
HY-13892 Related Classifications
Powered by Bioz